Omisirge
Payments companies reported to CMS as associated with Omisirge. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Omisirge, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Omisirge
These are the largest totals companies reported as associated with Omisirge. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Ivan Borrello | Tampa, FL | Medical Oncology | $182,619.00 |
| Stephanie Tsai | Maywood, IL | Hematology (Internal Medicine) | $33,613.63 |
| Filippo Milano | Seattle, WA | Hematology & Oncology | $21,886.49 |
| Mitchell Horwitz | Durham, NC | Infectious Disease | $16,240.39 |
| Julio Alvarenga Thiebaud | Dallas, TX | Hematology & Oncology | $12,733.43 |
| Jonathan Gutman | Aurora, CO | Medical Oncology | $11,670.00 |
| Mhd Monzr Al Malki | Duarte, CA | Hematology (Internal Medicine) | $11,560.01 |
| Paibel Aguayo-Hiraldo | Los Angeles, CA | Pediatric Hematology-Oncology | $10,733.31 |
| Christine Duncan | Boston, MA | Pediatric Hematology-Oncology | $10,722.00 |
| Manuel Espinoza-Gutarra | Birmingham, AL | Hematology & Oncology | $9,214.98 |
Prescribed Omisirge?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.